These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

898 related items for PubMed ID: 23775712

  • 1. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
    Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S, Liberati AM, Oliva S, Patriarca F, Offidani M, Omedé P, Montefusco V, Petrucci MT, Giuliani N, Passera R, Pietrantuono G, Boccadoro M, Corradini P, Palumbo A.
    Blood; 2013 Aug 22; 122(8):1376-83. PubMed ID: 23775712
    [Abstract] [Full Text] [Related]

  • 2. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.
    J Clin Oncol; 2010 Feb 10; 28(5):800-7. PubMed ID: 20048187
    [Abstract] [Full Text] [Related]

  • 3. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A, Cea M, Patriarca F, D'Agostino M, Capra A, Giuliani N, de Fabritiis P, Aquino S, Palmas A, Gamberi B, Zambello R, Petrucci MT, Corradini P, Cavo M, Boccadoro M.
    Lancet Oncol; 2021 Dec 10; 22(12):1705-1720. PubMed ID: 34774221
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A.
    Lancet Oncol; 2015 Dec 10; 16(16):1617-29. PubMed ID: 26596670
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
    Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K.
    Int J Clin Oncol; 2019 Aug 10; 24(8):966-975. PubMed ID: 30937622
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
    Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Chalmers A, O'Connor S, Drayson MT, Morris TC, National Cancer Research Institute Haemato-oncology Clinical Studies Group.
    Lancet Oncol; 2014 Jul 10; 15(8):874-85. PubMed ID: 24948586
    [Abstract] [Full Text] [Related]

  • 9. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
    Takamatsu H, Munemoto S, Murata R, Terasaki Y, Nakajima K, Nakao S.
    Anticancer Res; 2013 Dec 10; 33(12):5681-5. PubMed ID: 24324117
    [Abstract] [Full Text] [Related]

  • 10. Advances in therapy of multiple myeloma.
    Bladé J, Rosiñol L.
    Curr Opin Oncol; 2008 Nov 10; 20(6):697-704. PubMed ID: 18841053
    [Abstract] [Full Text] [Related]

  • 11. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
    Jakubowiak AJ, Griffith KA, Reece DE, Hofmeister CC, Lonial S, Zimmerman TM, Campagnaro EL, Schlossman RL, Laubach JP, Raje NS, Anderson T, Mietzel MA, Harvey CK, Wear SM, Barrickman JC, Tendler CL, Esseltine DL, Kelley SL, Kaminski MS, Anderson KC, Richardson PG.
    Blood; 2011 Jul 21; 118(3):535-43. PubMed ID: 21596852
    [Abstract] [Full Text] [Related]

  • 12. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
    Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa AM, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien ML, Facon T, Avet-Loiseau H, Attal M.
    J Clin Oncol; 2014 Sep 01; 32(25):2712-7. PubMed ID: 25024076
    [Abstract] [Full Text] [Related]

  • 13. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B, Li J, Liu J, Gu J, Zheng D, Xu D, Zou W, Wang H.
    Zhonghua Nei Ke Za Zhi; 2014 Nov 01; 53(11):865-72. PubMed ID: 25586356
    [Abstract] [Full Text] [Related]

  • 14. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.
    Ann Hematol; 2012 Feb 01; 91(2):249-56. PubMed ID: 21789621
    [Abstract] [Full Text] [Related]

  • 15. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.
    Cancer; 2010 Jul 01; 116(13):3143-51. PubMed ID: 20564642
    [Abstract] [Full Text] [Related]

  • 16. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec 01; 18(104):263-6. PubMed ID: 20025098
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M.
    J Clin Oncol; 2014 Mar 01; 32(7):634-40. PubMed ID: 24449241
    [Abstract] [Full Text] [Related]

  • 18. Treatment of newly diagnosed myeloma.
    Palumbo A, Rajkumar SV.
    Leukemia; 2009 Mar 01; 23(3):449-56. PubMed ID: 19005483
    [Abstract] [Full Text] [Related]

  • 19. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
    Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Béné MC, Zweegman S, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Stoppa AM, van de Donk NWCJ, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Krevvata M, Zhang K, de Boer C, Vara S, Kampfenkel T, Vanquickelberghe V, Vermeulen J, Avet-Loiseau H, Sonneveld P.
    Lancet Oncol; 2021 Oct 01; 22(10):1378-1390. PubMed ID: 34529931
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
    Tanimura A, Hirai R, Nakamura M, Takeshita M, Togano T, Sekine R, Hagiwara S, Miwa A.
    Gan To Kagaku Ryoho; 2020 May 01; 47(5):789-796. PubMed ID: 32408321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.